TTYP01

Phase 2Small molecule

SShanghai Auzone Biological Technology Co., Ltd.

TTYP01 is one of 48 small molecule programs targeting Efficacy and Safety. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Efficacy and SafetyRecruiting

Efficacy and SafetyPhase 2

Recruiting

Competition

Competitive Landscape

228 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Tuoyi

SSun Yat-sen University

Phase 3

4 2

Busulfex

Akero Therapeutics

Phase 3

3 3

Rilutek

AAzurity Pharmaceuticals

Phase 3

3 4

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 5

Alka-Seltzer

AAbbott

Phase 3

1 6

Oxycontin

PPurdue Pharma LP

Phase 3

1 7

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

4 8

Mitomycin C

GGynecologic Oncology Group

Phase 3

2 9

Avalglucosidase Alfa

Sanofi

Phase 3

1 10

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Early Alzheimer's Disease

NCT07252440

Clinical

Trials by Indication[1]

Adult Subject2 trials

Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects

Completed·SShanghai Auzone Biological Technology Co., Ltd.·Phase 1·NCT06107205·29 enrolled

A Study of TTYP01 in Healthy Adult Subjects

Completed·SShanghai Auzone Biological Technology Co., Ltd.·Phase 1·NCT04370431·72 enrolled

Ischemic stroke1 trial

Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic Stroke

Completed·SShanghai Auzone Biological Technology Co., Ltd.·Phase 3·NCT06648304·614 enrolled

Efficacy and Safety1 trial

Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD

Recruiting·SShanghai Auzone Biological Technology Co., Ltd.·Phase 2·NCT06757504·150 enrolled

Early Alzheimer's Disease1 trial

A Prospective, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease

Recruiting·SShanghai Auzone Biological Technology Co., Ltd.·Phase 2·NCT07252440·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for TTYP01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TTYP01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TTYP01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Auzone Biological Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Auzone Biological Technology Co., Ltd.

TTYP01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Adult Subject2 trials

Ischemic stroke1 trial

Efficacy and Safety1 trial

Early Alzheimer's Disease1 trial

References

Drug Info

Quick Facts

Related News